Autonomix long-term pancreatic cancer pain data accepted for presentation at DDW 2026
PUBT · 04/29 12:45
Share
Listen to the news
- Autonomix Medical announced abstract acceptance at Digestive Disease Week 2026 for long-term data on its transvascular radiofrequency ablation approach for pancreatic cancer pain mitigation.
- Results will be presented May 2-5, 2026, in Chicago and virtually.
- Long-term outcomes indicate the procedure can mitigate severe pain in pancreatic adenocarcinoma by disrupting nerve signaling pathways tied to pain transmission.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290845PRIMZONEFULLFEED9709039) on April 29, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved